Cheryl’s Liver Cancer Story
In my younger years, beginning around the age of 30, I was living fast and careless. I was the party girl, always drinking, never thinking about what it might one…
Continue Reading
Cheryl’s Liver Cancer Story
EMERALD‑3 Trial Shows Benefit of Dual Immunotherapy–Based Strategy in Embolization‑Eligible Liver Cancer
As reported on PharmaBiz, a novel treatment strategy combining dual immunotherapy, targeted therapy, and transarterial chemoembolization (TACE) has demonstrated meaningful clinical benefit for patients with unresectable hepatocellular carcinoma (HCC), according…
Continue Reading
EMERALD‑3 Trial Shows Benefit of Dual Immunotherapy–Based Strategy in Embolization‑Eligible Liver Cancer
source: shutterstock.com
Toripalimab Combined with Bevacizumab Meets Primary Endpoint for Advanced Hepatocellular Carcinoma
Shanghai's Junshi Biosciences Co. (The Company) recently announced in Biospace, that its product, toripalimab (TUOYI®), combined with bevacizumab as a first-line therapy for hepatocellular carcinoma (HCC), met its endpoints in a…
Continue Reading
Toripalimab Combined with Bevacizumab Meets Primary Endpoint for Advanced Hepatocellular Carcinoma
source: pixabay.com
Transfusions with Contaminated Blood Mean 1750 People in the UK Have Undiagnosed Hepatitis C
Blood transfusions are a vital medical procedure used to address a multitude of health conditions and emergencies, such as severe anemia, sepsis, trauma, internal bleeding, hemophilia, sickle cell disease, thalassemia,…
Continue Reading
Transfusions with Contaminated Blood Mean 1750 People in the UK Have Undiagnosed Hepatitis C
source: shutterstock.com
ASCO GI Symposium: Fostrox-Lenvima Combo Treatment Show Clinical Benefit in Treating HCC
Despite novel treatment advances, hepatocellular carcinoma (HCC) remains difficult to treat. This aggressive cancer is often not found until later stages and not all people with HCC can utilize available…
Continue Reading
ASCO GI Symposium: Fostrox-Lenvima Combo Treatment Show Clinical Benefit in Treating HCC
source: pixabay.com
Positive Signs from Interim Data in Early Hepatocellular Carcinoma Trial
According to a story from PR Newswire, the pharma company Medivir AB, which is focused on developing cancer therapies in areas of critical high unmet need, recently announced the release…
Continue Reading
Positive Signs from Interim Data in Early Hepatocellular Carcinoma Trial
https://unsplash.com/photos/8ztH-7lj8ag
New Drug Combo Improves Survival in Inoperable Liver Cancer Patients
The success of the CARES 310 Trial Phase III (NCT03764293 ) was reported this week in Biospace by Elevar Therapeutics. The combination of two drugs, rivocera, and camrelizumab proved to…
Continue Reading
New Drug Combo Improves Survival in Inoperable Liver Cancer Patients
PublicDomainPictures / Pixabay
EGFR and ERBB2-Mutated HCC Responds Poorly to Lenvatinib
In the past, doctors have noticed a trend in hepatocellular carcinoma (HCC). More specifically, research has shown that HCC can grow resistant to certain drugs. This makes it more…
Continue Reading
EGFR and ERBB2-Mutated HCC Responds Poorly to Lenvatinib
Source: Pixabay.com
Second-Line Lenvima Could Prolong HCC Survival
Despite medical advances and new therapeutic developments, hepatocellular carcinoma (HCC) remains difficult to treat; in part, this is due to the fact that HCC, like many liver cancers, is often…
Continue Reading
Second-Line Lenvima Could Prolong HCC Survival
source: unsplash.com
New Combination Therapy Approved in US for Unresectable Hepatocellular Carcinoma
According to a story from finance.yahoo.com, a new treatment regimen has been approved by the US Food and Drug Administration (FDA) for hepatocellular carcinoma that cannot be treated with surgery.…
Continue Reading
New Combination Therapy Approved in US for Unresectable Hepatocellular Carcinoma
source: unsplash.com
GNS561 Earns Orphan Drug Designation for Cholangiocarcinoma
According to an article from Cancer Network, the U.S. Food and Drug Administration (FDA) recently granted Orphan Drug designation to second-line GNS561 (ezurpimtrostrat) for cholangiocarcinoma (bile duct cancer). In…
Continue Reading
GNS561 Earns Orphan Drug Designation for Cholangiocarcinoma
source: pixabay.com
Study of the Week: Could This Protein Predict Diabetes and Cancer Death Risk?
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Continue Reading
Study of the Week: Could This Protein Predict Diabetes and Cancer Death Risk?
source: pixabay.com
Combination Therapy for Hepatocellular Carcinoma Fails to Achieve Trial Endpoints
According to a story from Market Watch, the drug companies Merch and Eisai recently announced an update on their phase 3 clinical trial. This clinical trial was evaluating a combination…
Continue Reading
Combination Therapy for Hepatocellular Carcinoma Fails to Achieve Trial Endpoints
source: pixabay.com
Porphyria Increases Liver Cancer Risk by 5%, Study Shows
Sometimes, certain health conditions can increase the risk of developing other conditions. According to a new research study, this may be the case with porphyria and hepatocellular carcinoma. An article…
Continue Reading
Porphyria Increases Liver Cancer Risk by 5%, Study Shows
Patients with Liver Diseases Causing Cirrhosis May Be Predisposed to HCC
Liver cirrhosis (scarring) can be fatal because damage to the liver is irreversible. A cirrhotic liver leads to liver failure, liver cancer, and eventually death. According to a report in…
Continue Reading
Patients with Liver Diseases Causing Cirrhosis May Be Predisposed to HCC
source: pixabay.com
LioCyx-M004 for HBV-Related Hepatocellular Carcinoma Earns Fast Track Designation
According to Healio, the U.S. Food and Drug Administration (FDA) recently granted Fast Track designation to LioCyx-M004. This therapy, developed by T-cell immunotherapy company Lion TCR, is designed to…
Continue Reading
LioCyx-M004 for HBV-Related Hepatocellular Carcinoma Earns Fast Track Designation
source: pixabay.com
CRISPR/Cas9 Gene Editing Adds Ultrasound Therapy for Hepatocellular Carcinoma to its List of Possibilities
Washington University Researchers readily acknowledge the attributes of sonodynamic therapy (SDT) as a promising therapeutic method to treat hepatocellular carcinoma (HCC). SDT is noninvasive with high tissue penetration, but…
Continue Reading
CRISPR/Cas9 Gene Editing Adds Ultrasound Therapy for Hepatocellular Carcinoma to its List of Possibilities
[Source: pixabay.com]
KEYTRUDA Met OS Endpoint in Hepatocellular Carcinoma Clinical Trial
Clinical trials have many endpoints - or milestones they are looking to achieve. These endpoints help signify the safety, efficacy, and tolerability of the treatments. In the Phase 3…
Continue Reading
KEYTRUDA Met OS Endpoint in Hepatocellular Carcinoma Clinical Trial
source: pixabay.com
Hepatocellular Carcinoma Gene Study Unveils New Potential Drug Target
According to a study published in PLOS Genetics, a recent genetic study of hepatocellular carcinoma (HCC) cancer tumors has revealed vital information that could one day lead to a new…
Continue Reading
Hepatocellular Carcinoma Gene Study Unveils New Potential Drug Target
An Escalating War on Liver Cancer
Liver cancer has been one of the leading causes of cancer-related deaths. A recent article in HemOnc Today reports that liver cancer is perhaps one of the most difficult cancers…
Continue Reading
An Escalating War on Liver Cancer
ArtTower / Pixabay
Health Canada Approves Cabometyx for Previously Treated Hepatocellular Carcinoma
According to a story from the Malvern Daily Record, the biotechnology company Exelixis, Inc. has recently announced that its partner company Ipsen BioPharmaceuticals Canada Inc. has had its drug cabozantinib…
Continue Reading
Health Canada Approves Cabometyx for Previously Treated Hepatocellular Carcinoma
Mice Model Shows Rapamycin May be Effective in Liver Cancer
There is a high unmet need to find more effective treatments for liver cancer. Currently, treatment options for patients often only increase life expectancy by 3 to 4 months. An accidental…
Continue Reading
Mice Model Shows Rapamycin May be Effective in Liver Cancer
Source: Pixabay.com
FDA Approves Drug for Previously Treated Hepatocellular Carcinoma Patients
According to an article from Global Banking & Financing Review, the California-based pharmaceutical company Exelixis, Inc. has announced the FDA's approval of their drug Cabometyx (cabozantinib) for patients previously diagnosed…
Continue Reading
FDA Approves Drug for Previously Treated Hepatocellular Carcinoma Patients
Source: Pixabay.com
Michael Bublé is Back to Making Music Following Son’s Liver Cancer Remission
The holiday season is upon us, and nothing says holiday cheer more than the smooth and sultry sounds of Michael Bublé singing Christmas tunes. In fact, Michael Bublé has been promoting…
Continue Reading
Michael Bublé is Back to Making Music Following Son’s Liver Cancer Remission
geralt / Pixabay
Artificial Intelligence Technology is Being Developed to Support the Treatment of Liver Cancer
The organisations Guerbet and IBM Watson Health are collaborating to develop an artificial intelligence tool designed to support the diagnosis and care of liver cancer. The source article can be…
Continue Reading
Artificial Intelligence Technology is Being Developed to Support the Treatment of Liver Cancer
